Scale -


  • Ebitda is 25.36 Rs Cr; Annual Growth is 77 %; in Top Quartile
  • PBT is -1.49 Rs Cr; Annual Growth is 37 %; in Bottom Quartile
  • PAT is -27.31 Rs Cr; Annual Growth is 37 %; in Bottom Quartile
  • Revenue is 345 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 13 %
  • Quarterly Profit is -3.56 Rs Cr; Continuous Growth over 3 Quarters; in Bottom Quartile

Profitability -


  • PBDIT Margin is 7.34 %; Annual Growth is 75 %; 5 Year CAGR is -19 %
  • PAT Margin is -7.9 %; Annual Growth is 38 %; in Bottom Quartile
  • Quarterly Profit margin is -4 %; Continuous Growth over 3 Quarters; in Bottom Quartile

Return -


  • ROCE is -1.94 %; Annual Growth is 60 %; in Bottom Quartile
  • ROA is -1.33 %; Annual Growth is 31 %; in Bottom Quartile
  • ROE is -2.54 %; Annual Growth is 33 %; in Bottom Quartile
  • Asset Turnover is 55 %; Continuous Decline over 3 years

Efficiency -


  • Operating cash flow is 38.36 Rs Cr; Annual Growth is 241 %; in Top Quartile
  • Current Ratio is 1.97; Continuous Growth over 3 years
  • Quick Ratio is 1.43; Continuous Growth over 3 years

Solvancy -


  • Contingent Liabilities is 34.51 Rs Cr; Annual Decline is -52 %; in Top Quartile
  • Debt/Equity is 0.45; Continuous Decline over 3 years; 5 Year CAGR is 42 %
  • Long term Debt is 122 Rs Cr; Annual Growth is 61 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 77 %
  • Total Debt is 146 Rs Cr; in Top Quartile; 5 Year CAGR is 69 %

Quality -


  • Operating cashflow/ebitda is 151 %; Annual Growth is 179 %; in Top Quartile
  • Current Tax/PAT is -25 %; Continuous Decline over 3 years; in Bottom Quartile
  • Operating cashflow/PAT is -140 %; Annual Decline is -325 %; in Bottom Quartile
  • Change in Inventories/Total Expenses is 1 %; Annual Growth is 1178 %; Continuous Growth over 3 years; in Top Quartile
  • Exceptional Items/PBT is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
20% Upper Circuit: Pharma Stock Skyrockets After Reporting 109% YoY Increase in Net Profit
Most Active Stocks Today: Sagility, Vodafone Idea
Stock Market Gainers and Losers Today: Trent, Infosys
Suzlon Sinks 8%, Sagility Down 5%; Vedanta Power Jumps 13%
Volume Gainers Today, 30 October 2026 at 11:45 AM IST: Borosil, Quick Heal and Bharat Parenterals Lead
Welspun Corp Q2 Net Profit Jumps 12% to Rs 495 Cr
Bharat Parenterals Q2 Results FY27: Revenue Up 110.89% to Rs 136.28 Cr, PAT Rs 11.82 Cr
Bharat Parenterals Q2FY27 Results: Net profit turns positive at ?11.8 crore
Bharat Parenterals Ltd. Estimates – BSE:BPLPHARMA
Bharat Parenterals revises EGM voting results to correct categorization
Bharat Parenterals schedules EGM on Oct 23 to approve ?139 crore preferential issue
Bharat Parenterals shines as its arm commences commercial supply to United States
Bharat Parenterals ?? ??????? Innoxel ?? ?????? ?????? ???? ????? ???? ?????? ?? ?????
Bharat Parenterals Innoxel US Pharmaceutical Supply Explained
Bharat Parenterals Subsidiary Innoxel Starts U.S. Commercial Sales With October 20 Launch
Innoxel Lifesciences commences U.S. commercial supply with launch of its first CMO product
Bharat Parenterals issues corrigendum on preferential issue disclosures